AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
The Perseus study presented at ASH 2023 highlights the significance of changing induction treatment in newly diagnosed myeloma patients. The study compared the efficacy of DARA RVD, followed by DARA land maintenance, with the standard RVD regimen. The results validate the use of combination therapies, specifically DARA RVD, as the preferred induction treatment, leading to improved progression-free survival (PFS) and enhanced depth of response. These findings support the need to consider adding anti-CD38 agents in the induction phase for optimal patient outcomes.